How Important Are Emerging Markets To Abbott?
Abbott derives approximately 50% of its sales from emerging markets. This is one key reason as to why Abbott’s sales are largely affected due to foreign currency fluctuations. The company’s sales declined by 8.3% or $1680 million in 2015 due to foreign currency losses.
Further, the company’s established pharmaceutical division operates only in emerging markets. In February 2015, Abbott completed the sale of its developed markets business to Mylan N.V. However, Abbott retained its branded generics pharmaceutical business and products of its Established pharmaceutical Products segment in emerging markets.
Notes:
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- Lower Testing Demand To Weigh On Abbott’s Q2?
- Will Abbott Stock Rebound To Its 2022 Highs?
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)